SELECT PUBLICATIONS

Agrawal A et al. Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 2007;101(1):123. Abstract

Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract

Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007;16(3):223-34. Abstract

Carmona-Bayonas A. Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer. Breast 2007;16(3):323-5. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant
treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006;24(21):e42-3. No abstract available

Giordano SH et al. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25(3):235-7. Abstract

Gomez HL et al. Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2006. Abstract 1090.

Gradishar W et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2007;Abstract 1032.

Gradishar W et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal
women with advanced breast cancer. San Antonio Breast Cancer Symposium 2006a;Abstract 12.

Gradishar W et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs q3w solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Presentation. San Antonio Breast Cancer Symposium 2006b;Abstract 46.

Henry LN et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2007;[Epub ahead of print]. Abstract

Martin M et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract

Miller K et al. Capecitabine plus bevacizumab in first line metastatic breast cancer: An interim safety and efficacy report of the first phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. San Antonio Breast Cancer Symposium 2006;Abstract 2068.

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.

Niwinska A et al. Effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival. Proc ASCO 2007;Abstract 1015.

Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.

Sledge G et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. Proc ASCO 2007;Abstract 1013.

Home | Search

EDITOR'S NOTE
Survivors
Neil Love, MD
- Select publications

INTERVIEWS
Ian E Smith, MD
- Select publications

Charles L Vogel, MD
- Select publications

Sandra M Swain, MD
- Select publications

Paul E Goss, MD, PhD
- Select publications

Hannah M Linden, MD
- Select publications

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office